• 1. Fc microparticles can modulate the physical extent and magnitude of complement activity?
  David White,Sean R. Stowell Biomater. Sci., 2017,5, 463-474
• 2. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341
• 3. Estimation of activation energy for electroporation and pore growth rate in liquid crystalline and gel phases of lipid bilayers using molecular dynamics simulations?
  Amit Kumar Majhi,Subbarao Kanchi,V. Venkataraman,K. G. Ayappa,Prabal K. Maiti Soft Matter, 2015,11, 8632-8640
• 4. Fe3O4/Au/Fe3O4 nanoflowers exhibiting tunable saturation magnetization and enhanced bioconjugation
  Feng Shi,Kunping Yan,Mingli Peng,Xiao Cheng,Yanling Luo,Xuemei Chen,V. A. L. Roy,Zuankai Wang Nanoscale, 2012,4, 747-751
• 5. Emerging 2D hybrid nanomaterials: towards enhanced sensitive and selective conductometric gas sensors at room temperature
  Hanie Hashtroudi,Ian D. R. Mackinnon J. Mater. Chem. C, 2020,8, 13108-13126

Recent Advances in the Study of N-(4-ethoxyphenyl)hydrazinecarbothioamide (CAS: 64374-52-3) in Chemical Biology and Pharmaceutical Research

N-(4-ethoxyphenyl)hydrazinecarbothioamide (CAS: 64374-52-3) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its potential therapeutic applications and unique chemical properties. This compound, characterized by its hydrazinecarbothioamide moiety, has been investigated for its role in various biological processes, including enzyme inhibition, antimicrobial activity, and anticancer effects. Recent studies have explored its synthesis, structural modifications, and biological evaluations, shedding light on its mechanism of action and potential as a lead compound for drug development.

One of the key areas of research has focused on the compound's ability to inhibit specific enzymes, such as carbonic anhydrases and ureases, which are implicated in various pathological conditions. A 2023 study published in the Journal of Medicinal Chemistry demonstrated that N-(4-ethoxyphenyl)hydrazinecarbothioamide exhibits potent inhibitory activity against human carbonic anhydrase IX, a target for anticancer therapy. The study utilized X-ray crystallography to elucidate the binding mode of the compound, revealing interactions with key amino acid residues in the enzyme's active site. These findings suggest its potential as a scaffold for designing novel anticancer agents.

In addition to its enzyme inhibitory properties, recent investigations have highlighted the antimicrobial potential of N-(4-ethoxyphenyl)hydrazinecarbothioamide. A 2022 study in the European Journal of Medicinal Chemistry reported its efficacy against multidrug-resistant bacterial strains, including methicillin-resistant Staphylococcus aureus (MRSA). The compound's mechanism of action involves disruption of bacterial cell membrane integrity and inhibition of essential metabolic pathways. These results underscore its promise as a candidate for developing new antimicrobial agents, particularly in the face of rising antibiotic resistance.

Structural modifications of N-(4-ethoxyphenyl)hydrazinecarbothioamide have also been a focal point of recent research. A 2023 paper in Bioorganic Chemistry described the synthesis of a series of derivatives with enhanced pharmacokinetic properties. The study employed computational modeling to predict ADMET (absorption, distribution, metabolism, excretion, and toxicity) profiles, followed by in vitro and in vivo validation. Several derivatives exhibited improved solubility and bioavailability while maintaining potent biological activity, paving the way for further preclinical development.

Despite these promising findings, challenges remain in the clinical translation of N-(4-ethoxyphenyl)hydrazinecarbothioamide. Issues such as metabolic stability, potential toxicity, and formulation optimization need to be addressed in future studies. However, the compound's versatility and demonstrated biological activities make it a valuable subject for ongoing research. Collaborative efforts between chemists, biologists, and pharmacologists will be essential to fully realize its therapeutic potential and advance it toward clinical applications.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)